Pharma/biotech giants Pfizer PFE and Bristol Myers BMY boast of a dominant position in the lucrative oncology space. Oncology ...

1 British Journal of Cancer volume 131, pages 601–610 (2024). 2 Cocco, E., Scaltriti, M., and Drilon, A. (2018). NTRK fusion-positive cancers and TRK inhibitor therapy. Nature Reviews Clinical ...

In February 2025, China’s NMPA granted priority review to repotrectinib for the treatment of adult patients with advanced solid tumors that have an NTRK gene fusion.. About Repotrectinib ...

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 21, 2025-- ...

TRK fusion cancer can occur in any part of the body. "The full approval of [larotrectinib] by [FDA] is a welcome step forward, solidifying its place as a treatment option for patients with NTRK gene ...

The FDA has granted full approval to Bayer’s Vitrakvi (larotrectinib), a first-in-class NTRK inhibitor, for the treatment of adult and pediatric patients with NTRK gene fusion-positive solid tumors.

Bayer’s Vitrakvi (larotrectinib) has been granted traditional approval by the US Food and Drug Administration (FDA) to treat neurotrophic receptor tyrosine kinase (NTRK) gene fusion-positive solid ...

Vitrakvi has demonstrated clinically meaningful and durable responses across various NTRK fusion-positive solid tumors. FDA first granted Vitrakvi accelerated approval in November 2018.

Vitrakvi received full FDA approval for treating NTRK gene fusion-positive solid tumors in adults and children, following its initial accelerated approval in 2018. The drug functions as a tyrosine ...

NTRK gene fusion is a rare genetic alteration found in tumors originating from various organs, including the lungs, thyroid, and intestines. VITRAKVI is indicated for patients with advanced or ...